Shares of Momenta Pharma (MNTA) are off 46% to $7.27, a 52-week low. The company said said Tuesday the Food and Drug Administration denied approval for its blood clot drug enoxaparin sodium, being developed with partner Novartis.
Douglas A. McIntyre
Mo
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
